Ashland Global Holdings logo

Ashland Global HoldingsNYSE: ASH

Profile

Country:

United States

IPO:

17 March 1980

Next earnings report:

30 January 2025

Last dividends:

30 August 2024

Next dividends:

29 November 2024
$3.57 B
-42%vs. 3y high
70%vs. sector
-34%vs. 3y high
59%vs. sector
-44%vs. 3y high
40%vs. sector
-42%vs. 3y high
55%vs. sector

Price

after hours | Tue, 19 Nov 2024 23:11:50 GMT
$75.80-$2.51(-3.21%)
$522.00 M$439.34 M
$522.00 M$16.00 M

Analysts recommendations

Institutional Ownership

ASH Latest News

Ashland Place Completes New Financing Facility for Crestone Air Partners, Air T, Inc. and Mill Road Capital
prnewswire.com12 November 2024 Sentiment: POSITIVE

NEW YORK , Nov. 12, 2024 /PRNewswire/ -- Ashland Place Finance LLC ("Ashland Place"), a commercial aviation financing platform, today announced the completion of a new facility financing the acquisition of a Boeing 737-800 for Crestone Air Partners, Inc. ("Crestone"), Air T, Inc. ("Air T") and Mill Road Capital Management LLC ("Mill Road"). This is the third transaction that the Ashland Place platform has completed with Crestone, having previously financed the acquisitions of three Boeing 737-800 freighters in January 2024 and four CFM56 engines in July 2022.

Ashland Inc. (ASH) Q4 2024 Earnings Call Transcript
seekingalpha.com09 November 2024 Sentiment: NEUTRAL

Ashland Inc. (NYSE:ASH ) Q4 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants William Whitaker - VP, Finance and Director, IR Guillermo Novo - Chair and CEO Kevin Willis - SVP and CFO Alessandra Faccin - SVP and GM, Life Sciences and Intermediates Jim Minicucci - SVP and GM, Personal Care Dago Caceres - SVP and GM, Specialty Additives Conference Call Participants Michael Sison - Wells Fargo James Cannon - UBS John Roberts - Mizuho Mike Harrison - Seaport Research Partners Operator Thank you for standing by. My name is Hermione and I will be your conference operator today.

Ashland to host live 2024 strategy update event for analysts and investors
globenewswire.com08 November 2024 Sentiment: POSITIVE

WILMINGTON, Del., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) will host a strategy update event for analysts and investors on Tuesday, December 10, 2024, in New York City. The company will provide an in-depth review of Ashland's strategic priorities, key initiatives and financial objectives while emphasizing a proactive approach to market uncertainty in fiscal year 2025.

Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024
globenewswire.com07 November 2024 Sentiment: POSITIVE

Ailawadhi, Sikander, M.D., Lead Investigator, to Present Iopofosine I 131 Efficacy and Safety Results from Phase 2 CLOVER-WaM Study

ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
prnewswire.com06 November 2024 Sentiment: POSITIVE

ROCKVILLE, Md. and SUZHOU, China , Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the latest results from three clinical studies of one of the company's key drug candidate, lisaftoclax (APG-2575), have been selected for presentations, including an Oral Report, at the 66th American Society of Hematology (ASH) Annual Meeting.

ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
prnewswire.com06 November 2024 Sentiment: POSITIVE

ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the latest results from three clinical studies of one of the company's key drug candidate, lisaftoclax (APG-2575), have been selected for presentations, including an Oral Report, at the 66th American Society of Hematology (ASH) Annual Meeting.

Unveiling Ashland (ASH) Q4 Outlook: Wall Street Estimates for Key Metrics
zacks.com05 November 2024 Sentiment: POSITIVE

Evaluate the expected performance of Ashland (ASH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
globenewswire.com05 November 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, today announced that an abstract highlighting initial clinical data from the Phase 1-2 study of IMPT-314 in large B-cell lymphoma will be presented by Sarah M. Larson, M.D., Associate Professor, Department of Medicine, Medical Director, Immune Effector Cell Therapy Program, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, at the 66th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, CA, December 7 – 10, 2024. IMPT-314 is a dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate being developed for patients with aggressive B-cell non-Hodgkin's lymphoma.

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
globenewswire.com05 November 2024 Sentiment: POSITIVE

CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
globenewswire.com05 November 2024 Sentiment: POSITIVE

– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –

What type of business is Ashland Global Holdings?

Ashland Global Holdings, Inc. is a company specializing in chemical substances. It is involved in the production and distribution of architectural coatings; adhesives for automotive, construction, energy, food and beverage, personal care, and pharmaceutical industries. The Specialty Ingredients segment offers industry products, technologies, and resources to solve formulation development and performance improvement tasks. The Composites segment manufactures and sells unsaturated polyester resins, vinyl ester resins, and gel coats. The Intermediates and Solvents segment produces butanediol and related derivatives, including tetrahydrofuran and N-methylpyrrolidone. The company was founded in 1924 and is headquartered in Covington, Kentucky.

What sector is Ashland Global Holdings in?

Ashland Global Holdings is in the Basic Materials sector

What industry is Ashland Global Holdings in?

Ashland Global Holdings is in the Specialty Chemicals industry

What country is Ashland Global Holdings from?

Ashland Global Holdings is headquartered in United States

When did Ashland Global Holdings go public?

Ashland Global Holdings initial public offering (IPO) was on 17 March 1980

What is Ashland Global Holdings website?

https://www.ashland.com

Is Ashland Global Holdings in the S&P 500?

No, Ashland Global Holdings is not included in the S&P 500 index

Is Ashland Global Holdings in the NASDAQ 100?

No, Ashland Global Holdings is not included in the NASDAQ 100 index

Is Ashland Global Holdings in the Dow Jones?

No, Ashland Global Holdings is not included in the Dow Jones index

When was Ashland Global Holdings the previous earnings report?

No data

When does Ashland Global Holdings earnings report?

The next expected earnings date for Ashland Global Holdings is 30 January 2025